Optimized production of insulin variant, a recombinant platelet aggregation inhibitor, by high cell-density fermentation of recombinant Escherichia coli.

Optimal conditions for a high cell-density fermentation of Escherichia coli strain harboring a recombinant anti-thrombosis insulin variant (named rAT-INS) were investigated by using fed-batch culture employing pH-stat method. The optimized main medium composition were glycerol 10 g/L, yeast extract 30 g/L, trypton 10 g/L, NaCl 5 g/L. The late-stage induction with 0.05 mM isopropyl-β-d- thiogalactopyranoside showed the highest productivity after 28 h of the fed-batch fermentation. This optimized process yielded about 150 mg of purified rAT-INS from 1 L of wet cell mass with high-homogeneity. The amino acid compositions and mass data of the purified rAT-INS were in good agreement with those as expected. Purified rAT-INS exhibited potent inhibitory activity of platelet aggregation. The in vivo assay showed that rAT-INS had a higher activity in prolonging the bleeding time in mice than native-insulin. The purified rAT-INS had almost no insulin receptor binding activity. Our study demonstrates the promise for mass production of novel recombinant antiplatelet agents.
(Copyright © 2018 Elsevier Inc. All rights reserved.)